Mesothelioma Risk Score: A New Prognostic Pretreatment, Clinical-Molecular Algorithm for Malignant Pleural Mesothelioma

Yeap, Beow Y.; Rienzo, Assunta De; Gill, Ritu R.; Oster, Michela E; Dao, Mary N.; Dao, Nhien; Levy, Rachel; Vermilya, Kimberly; Gustafson, Corinne E.; Ovsak, Gavin; Richards, William G.; Bueno, Raphael

doi:10.1016/j.jtho.2021.06.014

Cited by 20 publications

(19 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recently published paper has presented the Mesothelioma Risk Score, a new model which combines pre-treatment parameters gained from imaging (e.g., tumour volume), tumour biopsy (e.g., molecular subtypes) and blood tests (e.g., neutrophil to lymphocyte ratio) to assess the expected outcome of surgery and improve patient stratification [ 52 ].…”

Section: How To Predict Tumour Response?mentioning

confidence: 99%

Malignant Pleural Mesothelioma Nodal Status: Where Are We at?

Ricciardi

Carleo

Jaus

et al. 2021

JCM

View full text Add to dashboard Cite

Due to the lack of both prospective trial and high-volume retrospective studies, the management of clinical N+ malignant pleural mesothelioma (MPM) patients remains highly debated. Node positive patients show poor survival compared with node-negative ones; thus, lymph node staging appears crucial in determining treatment strategy. Notwithstanding the improvement in pre-treatment staging and the update on lymph node classification in the 8th edition of TNM, several open controversies remain on N parameter. How should we stage suspected N+ patients? How should we treat node positive patients? Which is the definition of a “resectable patient”? Is the site or the number the main prognostic factor for node positive patients? The aim of our narrative review is to analyse the existing relevant literature on lymph node status in MPM.

show abstract

Section: How To Predict Tumour Response?mentioning

confidence: 99%

Malignant Pleural Mesothelioma Nodal Status: Where Are We at?

Ricciardi

Carleo

Jaus

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Many clinically based prognostic scoring systems have mainly been based on highly selected clinical trial populations, selected for their fitness for attempts at surgical treatment and/or chemotherapy [106][107][108]. Consequently, these are not generalisable and have not been widely utilised.…”

Section: Prognosismentioning

confidence: 99%

“…The most consistently reported variables associated with a poor prognosis have been older age [95,96,[109][110][111][112][113], male sex [95,110,112] and sarcomatoid histological characteristics [95,96,109,[111][112][113]. A recent prognostic model in MPM patients who had undergone surgery sought to combine tumour characteristics and patient phenotype, reporting that tumour volume, molecular expression subtype, NLR, Eastern Cooperative Oncology Group performance status (ECOG PS) and serum albumin were all associated with survival [106].…”

Section: Prognosismentioning

confidence: 99%

Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma

Brims

2021

Cancers

View full text Add to dashboard Cite

Mesothelioma is a cancer predominantly of the pleural cavity. There is a clear association of exposure to asbestos with a dose dependent risk of mesothelioma. The incidence of mesothelioma in different countries reflect the historical patterns of commercial asbestos utilisation in the last century and predominant occupational exposures mean that mesothelioma is mostly seen in males. Modern imaging techniques and advances in immunohistochemical staining have contributed to an improved diagnosis of mesothelioma. There have also been recent advances in immune checkpoint inhibition, however, mesothelioma remains very challenging to manage, especially considering its limited response to conventional systemic anticancer therapy and that no cure exists. Palliative interventions and support remain paramount with a median survival of 9–12 months after diagnosis. The epidemiology and diagnosis of mesothelioma has been debated over previous decades, due to a number of factors, such as the long latent period following asbestos exposure and disease occurrence, the different potencies of the various forms of asbestos used commercially, the occurrence of mesothelioma in the peritoneal cavity and its heterogeneous pathological and cytological appearances. This review will describe the contemporary knowledge on the epidemiology of mesothelioma and provide an overview of the best clinical practice including diagnostic approaches and management.

show abstract

“…Several previously described PM prognostic scores are based on patients undergoing chemotherapy, 62,63 while surgical‐based models have been limited 64–66 . Multimodality prognostic score (MMPS), presented by Opitz et al, 64 was based on 128 patients undergoing induction chemotherapy followed by EPP.…”

Section: Introductionmentioning

confidence: 99%

Contemporary issues in the surgical management of pleural mesothelioma

Paajanen

Jaklitsch

Bueno

2023

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

The surgical management of pleural mesothelioma (PM) can be divided into diagnostic, staging, palliation, and cytoreductive surgery. In the cytoreductive surgical setting, the combination of different treatment modalities has led to better outcomes than surgery alone. The scarcity of high-quality studies has led to heterogeneity in management of PM across the mesothelioma treatment centers.Here, we review the literature regarding the most important open questions and ongoing clinical trials.

show abstract

Mesothelioma Risk Score: A New Prognostic Pretreatment, Clinical-Molecular Algorithm for Malignant Pleural Mesothelioma

Cited by 20 publications

References 34 publications

Malignant Pleural Mesothelioma Nodal Status: Where Are We at?

Malignant Pleural Mesothelioma Nodal Status: Where Are We at?

Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma

Contemporary issues in the surgical management of pleural mesothelioma

Contact Info

Product

Resources

About